Unveiling 3 Analyst Insights On Arcturus Therapeutics
Portfolio Pulse from Benzinga Insights
Three analysts have recently provided ratings on Arcturus Therapeutics (NASDAQ:ARCT), with two being bullish and one somewhat bullish. The average 12-month price target has increased to $65.33, reflecting a 6.23% rise from the previous target. Arcturus Therapeutics, an RNA medicines company, has shown significant revenue growth and maintains a strong market position despite some financial challenges.
October 01, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics has received positive analyst ratings, with an increased average price target of $65.33. The company shows strong revenue growth but faces challenges in ROE and ROA. Its low debt-to-equity ratio is a positive indicator.
The increase in the average price target and the bullish sentiment from analysts suggest a positive short-term impact on ARCT's stock price. The company's strong revenue growth and low debt-to-equity ratio are favorable, although challenges in ROE and ROA may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100